false
English
Catalog
2024 World Conference on Lung Cancer (WCLC) - Post ...
P4.11E.27 Comparison of Immunotherapy for Metastat ...
P4.11E.27 Comparison of Immunotherapy for Metastatic Non-Small Cell Lung Cancer in Real-World Practice: A Japanese Registry Study
Back to course
Pdf Summary
This study, conducted by the Osaka International Cancer Institute in Japan, retrospectively compares various immunotherapy regimens for metastatic non-small cell lung cancer (NSCLC) without driver alterations, using Japanese registry data from 68 cancer care hospitals collected between 2019 and 2021. The aim was to inform regimen selection by assessing overall survival (OS) and time to treatment failure (TTF).<br /><br />The study identified immune-chemo therapy as significantly more effective in improving OS compared to immune-mono therapy for stage IV NSCLC patients eligible for chemotherapy. Among the regimens analyzed, Pembro-chemo therapy notably improved both TTF and OS over ATZ-chemo therapy, though it showed similar results when compared to NIVIPI-chemo therapy. These findings emphasize the importance of well-informed regimen selection but also highlight the need for further research due to the limitations inherent in this study's retrospective nature and reliance on registry data. Factors such as significant differences in baseline patient characteristics, incomplete imaging data, incomplete data on PD-L1 TPS, and a lack of toxicity evaluations were noted.<br /><br />The study underscores the need for prospective trials with standardized criteria for regimen selection to fully validate these findings while pointing to Pembro-chemo therapy as a potentially superior option for this patient group. These insights contribute to the evolving oncology landscape by emphasizing more effective treatment pathways for metastatic NSCLC in real-world clinical practice.
Asset Subtitle
Akito Miyazaki
Meta Tag
Speaker
Akito Miyazaki
Topic
Metastatic NSCLC – Immunotherapy
Keywords
Osaka International Cancer Institute
immunotherapy regimens
metastatic NSCLC
Japanese registry data
overall survival
time to treatment failure
immune-chemo therapy
Pembro-chemo therapy
retrospective study
prospective trials
×
Please select your language
1
English
5
普通话
11
Dutch